Applied DNA Sciences, Inc. develops and markets DNA-based technology solutions for use in the nucleic acid-based in vitro diagnostics and preclinical nucleic-acid based drug development and manufacturing markets; and for supply chain security, anti-counterfeiting, and anti-theft technology purposes. The company's supply chain security and product authentication solutions include SigNature molecular tags that provide forensic power and protection for various applications used to fortify brand protection efforts and strengthen supply chain security, as well as mark, track, and convict criminals; SigNify IF portable DNA readers and SigNify consumable reagent test kits that provide real-time authentication of molecular tags in the field; and CertainT, which indicates the use of tagging, testing, and tracking platforms and solutions enabling manufacturers, brands, and trade organizations to convey proof of their product claims. It also manufactures and sells COVID-19 PCR-based molecular diagnostic test kit under the LineaTM COVID-19 Assay Kit trademark; and COVID-19 diagnostic test kit to prevent virus spread within a community, school, or workplace under the safeCircle trademark. In addition, the company provides preclinical contract research and manufacturing services for the nucleic acid-based therapeutic markets; and contract research services to RNA based drug and biologic customers for preclinical studies. Further, it develops an invasive circulating tumor cell capture and identification technology that uses a patented functional assay to capture live invasive circulating tumor cell and associated lymphocytes. The company operates in the United States, Europe, Asia, and internationally. The company was formerly known as Datalink Systems, Inc. and changed its name to Applied DNA Sciences, Inc. in 2002. Applied DNA Sciences, Inc. was founded in 1983 and is headquartered in Stony Brook, New York.
Employees - 46,
CEO - Dr. James A. Hayward Ph.D., Sc.D.,
Sector - Healthcare,
Country - US,
Market Cap - 3.88M
Altman ZScore(max is 10): -39.36, Piotroski Score(max is 10): 4, Working Capital: $6536108, Total Assets: $13035663, Retained Earnings: $-354442994, EBIT: -13043744, Total Liabilities: $2811455, Revenue: $3790617
- Current Price $0.60 - Analyst Target Price $75.00Ticker | APDN |
Index | - |
Curent Price | 0.60 |
Change | -7.47% |
Market Cap | 3.88M |
Average Volume | 1.33M |
Income | -46.19M |
Sales | 3.79M |
Book Value/Share | 1.65 |
Cash/Share | 1.05 |
Dividend Est | - |
Dividend TTM | - |
Dividend Ex-Date | - |
Employees | 48 |
Moving Avg 20days | -27.59% |
Moving Avg 50days | -57.43% |
Moving Avg 200days | -96.79% |
Shares Outstanding | 6.50M |
Earnings Date | May 15 AMC |
Inst. Ownership | 9.27% |
Price/Earnings | - |
Forwad P/E | - |
PE Growth | - |
Price/Sales | 1.02 |
Price/Book | 0.36 |
Price/Cash | 0.57 |
Price/FCF | - |
Quick Ratio | 4.27 |
Current Ratio | 4.45 |
Debt/Equity | 0.04 |
Return on Assets | -66.28% |
Return on Equity | -141.39% |
Return on Investment | -441.56% |
Gross Margin | 30.51% |
Ops Margin | -344.11% |
Profit Margin | -1218.46% |
RSI | 20.59 |
BETA(β) | 0.15 |
From 52week Low | -5.24% |
From 52week High | -99.66% |
EPS | -35.78 |
EPS next Year | -5.50 |
EPS next Qtr | -2.50 |
EPS this Year | 73.63% |
EPS next 5 Year | - |
EPS past 5 Year | 60.68% |
Sales past 5 Year | 60.75% |
EPS Y/Y | 95.84% |
Sales Y/Y | -31.30% |
EPS Q/Q | 94.22% |
Sales Q/Q | 5.78% |
Sales Surprise | -17.01% |
EPS Surprise | -411.67% |
ATR(14) | 0.12 |
Perf Week | -24.64% |
Perf Month | -26.30% |
Perf Quarter | -92.71% |
Perf Year | -99.57% |
Perf YTD | -94.15% |
Target Price | 75.00 |
AryaFin Engine© - An AI FinTech Venture - 2024-25 Disclaimer